Cancer Immunotherapy Month
To celebrate Cancer Immunotherapy Month this June, we are highlighting our researchers who have helped pioneer this research and continue to make seminal advances in this growing field.
Steven Rosenberg was the first to demonstrate that an immunotherapy could cure certain patients with metastatic disease, and he opened the doors to cell-based immunotherapies. Read more about the development of cancer immunotherapy. He and his team continue to refine these approaches.
Christian Hinrichs is researching cancer immunotherapy approaches to help patients with metastatic cancers caused by the human papilloma virus (HPV).
James Kochenderfer is focusing on genetically engineered T cells, called chimeric antigen receptor or CAR T cells, for the treatment of B-cell lymphomas and leukemias.
James Gulley is studying the use of cancer vaccines and other immunostimulatory molecules to modify the immune system’s response in cancer patients.
Thomas Waldmann co-discovered a cytokine called IL-15 and led the first-in-human clinical trial of this agent in patients with metastatic cancer. Read more about CCR's role in the discovery of cytokines.
Ira Pastan pioneered the development of immunotoxins to treat cancer, including successful treatments for refractory hairy-cell leukemia. He and Dr. Raffit Hassan have recently made advances towards treating mesothelioma with immunotoxins.
William L. Dahut primary mission is to improve therapy for men with advanced prostate cancer. He has pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy and other more traditional modalities.
James C. Yang has been involved in the clinical and scientific study of T-cell adoptive therapy and other immunotherapies to treat melanoma and other cancers.
Jeffrey Schlom directs a translational research program in cancer immunotherapy. He has pioneered the use of novel immunotherapeutics, both as monotherapy and in combination therapies, for a range of human cancers.
Eytan Ruppin has become actively engaged in collaborative studies in cancer immunotherapy, ranging from studying the role of urea cycle dysregulation in modulating the response to checkpoint inhibitors in different cancer types, studying the role of intratumor heterogeneity in shaping the immune response and its effectiveness, and very recently, building machine learning based predictors of patients’ response to checkpoint therapies in melanoma.
Luca Gattinoni is focused on understanding the transcriptional, metabolic, and microRNA-mediated regulation of T cell self-renewal and multipotency with the goal of developing new T cell-based immunotherapies for the treatment of patients with advanced cancer and hematologic malignancies.
George N. Pavlakis section designs, develops and tests vaccines and immunotherapies for AIDS and cancer. They study the role and application of cytokines in vaccines and cancer immunotherapy.
Jennifer Clare Jones current research is focused on developing immune-based therapies that synergize with radiation to produce optimal anti-tumor immune responses.
Claudia M. Palena investigates innovative immunotherapeutic approaches that may be used in combination with other anti-neoplastic agents to generate anti-tumor immune responses that could alleviate metastatic disease in cancer patients.
Tim F. Greten is currently studying novel immune-based approaches to treat patients with hepatocellular carcinoma, cholangiocarcinoma and tumors of the GI tract metastasizing into the liver. He is also principle investigator of several immunotherapy trials in patients with GI cancer.